Observational study on Epithelioid Sarcoma
Epithelioid Sarcoma. An Observational Study
This study looks at people with Epithelioid Sarcoma to better understand the disease and its two types, hoping to improve treatment and outcomes for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Italian Sarcoma Group Research network |
| Locations | 11 sites (Meldola, FC and 10 other locations) |
| Trial ID | NCT03099681 on ClinicalTrials.gov |
What this trial studies
This prospective national study in Italy aims to describe the population affected by Epithelioid Sarcoma (ES) and provide insights into the natural history of the disease. It will address outstanding questions regarding the management of ES and focus on the differences between its two variants: classical-type and proximal-type. The goal is to enhance understanding of the disease, tailor treatment approaches, and ultimately improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals with a histological diagnosis of Epithelioid Sarcoma who can provide informed consent and comply with treatment or follow-up.
Not a fit: Patients with other malignancies within the past five years, except for certain skin cancers, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with Epithelioid Sarcoma.
How similar studies have performed: While this study focuses on a specific population and disease variant, similar observational studies have provided valuable insights into rare cancers, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria 1. Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen 2. Signed informed consent 3. Adequate patient compliance to treatment or follow up 4. No age limit Exclusion criteria 1. Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent 2. Impossibility to ensure adequate compliance
Where this trial is running
Meldola, FC and 10 other locations
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST — Meldola, Fc, Italy (Recruiting)
- Istituto Europeo di Oncologia — Milan, Mi, Italy (Recruiting)
- Istituto Clinico Humanitas — Rozzano, Mi, Italy (Recruiting)
- Azienda Ospedaliera Universitaria Paolo Giaccone — Palermo, PA, Italy (Recruiting)
- Fondazione del Piemonte per l'Oncologia IRCC Candiolo — Candiolo, Torino, Italy (Recruiting)
- Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors — Bologna, Italy (Recruiting)
- Fondazione IRCCS INT Milano — Milan, Italy (Recruiting)
- Irccs Istituto Oncologico Veneto (Iov) — Padova, Italy (Recruiting)
- Ospedale Misericordia e Dolce Ist. Toscano Tumori, Az. USL4 — Prato, Italy (Recruiting)
- Campus Biomedico — Roma, Italy (Recruiting)
- Istituti Fisioterapici Ospitalieri di Roma — Roma, Italy (Recruiting)
Study contacts
- Principal investigator: Paolo Casali, MD — Fondazione IRCCS INT Milano
- Study coordinator: Annamaria Frezza, MD
- Email: annamaria.frezza@istitutotumori.mi.it
- Phone: 003902390
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.